Evidence map›Paper›PMID 30882096›Full record

ArticleJournal of rare diseases research & treatment2017

Commentary: SU9516 increases α7β1 Integrin and Ameliorates Disease Progression in the mdx Mouse Model of Duchenne Muscular Dystrophy.

Apurva Sarathy, Andreia M Nunes, Tatiana M Fontelonga, Tracy Y Ogata, Dean J Burkin

Abstract readComment
PubMed Full text at PMC
In one paragraph

Article in Journal of rare diseases research & treatment, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors.

Apurva SarathyDepartment of Pharmacology, University of Nevada, Reno School of Medicine, Reno, NV 89557, USA.
Andreia M NunesDepartment of Pharmacology, University of Nevada, Reno School of Medicine, Reno, NV 89557, USA.
Tatiana M FontelongaDepartment of Pharmacology, University of Nevada, Reno School of Medicine, Reno, NV 89557, USA.
Tracy Y OgataDepartment of Pharmacology, University of Nevada, Reno School of Medicine, Reno, NV 89557, USA.
Dean J BurkinDepartment of Pharmacology, University of Nevada, Reno School of Medicine, Reno, NV 89557, USA.

Funding

Laminin protein therapy for Congenital Muscular DystrophyR01AR064338 · NIAMS · UNIVERSITY OF NEVADA RENO · PI BURKIN, DEAN J. · 2014 to 2018
$1.6M
A drug-based approach for integrin-mediated alleviation of muscular dystrophyR21NS058429 · NINDS · UNIVERSITY OF NEVADA RENO · PI BURKIN, DEAN J. · 2007 to 2010
$388k
Galectin 1: A novel small protein therapy for Duchenne muscular dystrophyR41AR067014 · NIAMS · STRYKAGEN CORPORATION · PI BURKIN, DEAN J. · 2014 to 2015
$225k
NIAMS NIH HHS R01 AR064338NIAMS NIH HHS R41 AR067014NINDS NIH HHS R21 NS058429
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID30882096
PMCPMC6417831

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.